Editas Medicine shares are trading higher after Stifel upgraded the stock from Hold to Buy and raised its price target from $9 to $17.
Portfolio Pulse from Benzinga Newsdesk
Stifel has upgraded Editas Medicine from Hold to Buy and raised its price target from $9 to $17, leading to a rise in the company's shares.
September 29, 2023 | 1:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Editas Medicine's stock has been upgraded by Stifel from Hold to Buy, with a raised price target from $9 to $17. This has resulted in a rise in the company's shares.
The upgrade from Stifel is a positive signal for investors, indicating increased confidence in the company's prospects. The raised price target suggests that Stifel expects the stock to perform well in the short term, which has led to increased buying pressure and a rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100